Medical Device and Pharmaceutical News
The latest information of interest to regulated industry. Bookmark this page to have a quick review for
-
- FDA enforcement news
- Regulatory updates
- Innovative products
- Compliance information, and
- Other industry headlines.
And do not forget to check our pages for consumer safety information and regulatory services.
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
Class 1 Recall for HemosIL AcuStar HIT Antibody Test
HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...
Closing the Arterial Opening Without Surgery
Vivasure Medical's PerQseal Elite offers a minimally invasive approach to closing large arterial openings following cardiovascular procedures.Vivasure Medical's PerQseal Elite offers a minimally invasive approach to closing large arterial openings following...
FDA Approves Amplatzer Paraclose for Heart Valve Leaks
Abbott's Amplatzer Paraclose PVL Occluder offers a minimally invasive alternative for patients who develop a significant complication following heart valve replacement surgery.Heart valve replacement surgery can be lifesaving for patients with damaged or diseased...
FDA Approves Treatment for Advanced Head and Neck Cancer
Rybrevant Faspro receives accelerated approval following promising clinical trial results in patients with limited treatment options.The U.S. Food and Drug Administration (FDA) announced on November 5, 2026, that it has granted accelerated approval to Rybrevant Faspro...
FDA Approves Treatment that Targets SMA Muscle Loss
Isembyld introduces a new treatment approach for patients with SMA by addressing muscle weakness alongside existing therapies targeting the underlying genetic disease.The U.S. Food and Drug Administration (FDA) has approved Isembyld (apitegromab-mstn), the first...
October 2026 Premarket Approval (PMA) Authorizations
Three original device approvals and 218 supplements / noticesFDA's October activity highlights three newly approved medical devices and the extensive regulatory oversight required to maintain and modify products already on the market.The U.S. Food and Drug...
FDA Cell and Gene Therapy Potency Guidance
Eight Practical Implications for ManufacturersFDA's November 2026 final guidance moves beyond potency testing to emphasize a comprehensive, risk-based strategy for assuring product potency throughout development, manufacturing, and patient delivery.FDA'S final...
Final Guidance on Potency Assurance for Cell and Gene Therapies
New guidance emphasizes a science- and risk-based approach to ensuring product potency throughout development, manufacturing, and commercialization.On November 2, 2026, the U.S. Food and Drug Administration (FDA) issued final guidance, Potency Assurance for Cellular...